Brief: Alligator Bioscience & Aptevo Therapeutics Announce Dosing Of First Patient With ALG.APV-527 In Phase 1 Clinical Trial
13/02/2023 13:19
Feb 13 (Reuters) - Aptevo Therapeutics Inc APVO.O :
* ALLIGATOR BIOSCIENCE & APTEVO THERAPEUTICS ANNOUNCE DOSING
OF
FIRST PATIENT WITH ALG.APV-527 IN PHASE 1 CLINICAL TRIAL
* APTEVO THERAPEUTICS INC - LOOK FORWARD TO SHARING
PRELIMINARY
RESULTS, WHICH WE ANTICIPATE WILL BE AVAILABLE IN 2023
Source: (shorturl.at/bhkX0)
Further company coverage: APVO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aptevo Therapeutics
See all newsBrief: Aptevo Therapeutics - Enters Amendment No. 6 To Rights Agreement On October 23, 2026 - SEC Filing
U.S. STOCKS ON THE MOVE-Principal Financial Group, NetApp
U.S. STOCKS ON THE MOVE-Genesco, Fervo Energy, Tyson Foods
Aptevo Therapeutics reports early data for blood cancer therapy; shares fall
Aptevo Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary